Cargando…
Serostatus testing and dengue vaccine cost–benefit thresholds
The World Health Organization (WHO) currently recommends pre-screening for past infection prior to administration of the only licensed dengue vaccine, CYD-TDV. Using a threshold modelling analysis, we identify settings where this guidance prohibits positive net-benefits, and are thus unfavourable. G...
Autores principales: | Pearson, Carl A. B., Abbas, Kaja M., Clifford, Samuel, Flasche, Stefan, Hladish, Thomas J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Royal Society
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6731500/ https://www.ncbi.nlm.nih.gov/pubmed/31431184 http://dx.doi.org/10.1098/rsif.2019.0234 |
Ejemplares similares
-
Exploring the role of competition induced by non-vaccine serotypes for herd protection following pneumococcal vaccination
por: Masala, G. L., et al.
Publicado: (2017) -
Serological inference of past primary and secondary dengue infection: implications for vaccination
por: Lam, Ha Minh, et al.
Publicado: (2019) -
Estimating the fitness cost and benefit of antimicrobial resistance from pathogen genomic data
por: Helekal, David, et al.
Publicado: (2023) -
Estimating the distance to an epidemic threshold
por: O'Dea, Eamon B., et al.
Publicado: (2018) -
Hyperendemicity associated with increased dengue burden
por: Lim, Jue Tao, et al.
Publicado: (2021)